|1.||Sanderson, Ralph D: 22 articles (01/2015 - 01/2002)|
|2.||Park, Pyong Woo: 14 articles (11/2015 - 11/2002)|
|3.||Götte, Martin: 13 articles (11/2013 - 04/2002)|
|4.||Johansson, Pär I: 12 articles (02/2015 - 01/2011)|
|5.||Ostrowski, Sisse R: 11 articles (02/2015 - 01/2011)|
|6.||Kovalszky, Ilona: 10 articles (04/2014 - 01/2004)|
|7.||Dobra, Katalin: 9 articles (10/2015 - 01/2009)|
|8.||Kiesel, Ludwig: 9 articles (05/2013 - 01/2006)|
|9.||Edwards, Iris J: 9 articles (01/2013 - 05/2005)|
|10.||Yang, Yang: 8 articles (09/2009 - 07/2002)|
08/01/2003 - "In general, higher levels of syndecan-1 expression were observed in the well-differentiated tumors, in contrast to significant reduction of expression seen in poorly differentiated tumors. "
04/01/2014 - "In the present study we discovered that commonly used anti-myeloma drugs stimulate syndecan-1 shedding both in vitro and in animals bearing myeloma tumors. "
09/01/2012 - "Recent studies have demonstrated that syndecan-1 may have a different function and biological activity depending on the specific tumor type. "
01/01/2011 - "In the present study, we aimed to investigate the role of syndecan-1 in tumor cell adhesion and migration, with special focus on the importance of its distinct protein domains, to better understand the structure-function relationship of syndecan-1 in tumor progression. "
09/18/2009 - "High levels of shed syndecan-1 in the serum of patients are an indicator of poor prognosis, and numerous studies have implicated syndecan-1 in promoting the growth and progression of this cancer. "
06/01/2011 - "The protective effects of plasma may be due in part to its ability to restore the endothelial glycocalyx and preserve syndecan-1 after hemorrhagic shock."
09/01/2013 - "We have recently demonstrated that injured patients in hemorrhagic shock shed syndecan 1 and that the early use of fresh frozen plasma (FFP) in these patients is correlated with improved clinical outcomes. "
01/01/2015 - "While many studies have observed increased shedding of syndecan-1 during hemorrhagic shock, little is known about the shedding of other EGL components, and their effects on altered permeability and coagulation. "
11/01/2015 - "Plasma-Mediated Gut Protection After Hemorrhagic Shock is Lessened in Syndecan-1-/- MICE."
06/01/2015 - "Syndecan-1 restitution by plasma after hemorrhagic shock."
10/01/2013 - "The goal of the study was to examine syndecan-1 expression in breast carcinoma and its prognostic significance. "
01/01/2010 - "In the present study, we focused on the role of syndecan-1 in human urothelial carcinoma of the urinary bladder. "
12/01/2004 - "In this study we investigated breast carcinomas for the immunohistochemical expression of syndecan-1 protein and these results were assessed in relation to clinicopathological parameters, in order to clarify its prognostic value. "
12/01/2004 - "Clinicopathological study of the expression of syndecan-1 in invasive breast carcinomas. "
12/01/1999 - "The purpose of this study was to analyze syndecan-1 expression in invasive cervical carcinoma and to examine the association of syndecan-1 expression with prognostic factors and overall survival. "
08/01/2015 - "Shedding of syndecan-1, reflected by soluble syndecan-1 serum concentrations, is highly regulated by inflammation. "
01/01/2015 - "We hypothesize that antagonizing HS/syndecan-1 binding of the inflammatory effectors could reduce smoking-related neutrophil-mediated airway inflammation. "
01/01/2014 - "Syndecan-1 in the mouse parietal peritoneum microcirculation in inflammation."
04/01/2013 - "Syndecan-1 is involved in the processes of cell growth, differentiation, adhesion, wound healing and inflammation. "
07/01/2012 - "In vivo, intestinal permeability, inflammation, and injury were increased after gut IR in wild-type mice and further increased in syndecan 1 KO mice. "
|5.||Neoplasm Metastasis (Metastasis)
02/01/2004 - "Expression of syndecan-1 was significantly greater in soft tissue than in bone metastasis (P = 0.048, Fisher's exact test). "
10/01/2015 - "Finally, lung metastasis formation of A549 cells in SCID mice was found to be dependent on syndecan-1, and the presence of syndecan-1 tCTF was sufficient for this activity. "
01/01/2015 - "This meta-analysis indicated that loss of syndecan-1 expression is associated with CRC development, histological differentiation, and clinical stage, but not with lymph node metastasis and distant metastasis. "
01/01/2015 - "Additionally, syndecan-1 expression was higher in well and moderately differentiated CRC than in poorly differentiated CRC (OR = 2.91, 95 % CI = 1.21-6.98); no significant difference was found in patients with or without lymph node metastasis (OR = 0.91, 95 % CI = 0.34-2.43) and distant metastasis (OR = 0.89, 95 % CI = 0.19-4.21). "
03/01/2014 - "Shed syndecan-1 in turn controls tumour growth, metastasis and neo-angiogenesis mainly by promoting growth-factor signaling in the tumour milieu. "
|2.||Heparitin Sulfate (Heparan Sulfate)
|9.||Heparan Sulfate Proteoglycans (Heparan Sulfate Proteoglycan)
|10.||Omega-3 Fatty Acids (Omega 3 Fatty Acids)
|2.||Heterologous Transplantation (Xenotransplantation)
|3.||Homologous Transplantation (Allograft)
|4.||Transplantation (Transplant Recipients)